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Abstract 
Background: Clinical laboratory tests are important for clinicians to make diagnostic 
decisions, but discrepancies may directly lead to incorrect diagnosis. We would like to 
introduce some statistical methods to evaluate the comparability of chemistry analytes 
while comparing the performances of different measurement systems.
Methods: We used a panel of 10 fresh-frozen single donation serum samples to assess 
assays for the measurement of glucose and other 13 analytes. Statistical methods used 
in this article include traditional statistical analysis, robust statistics, regression analy-
sis and differences on medical decision levels (MDL). All the statistical analysis results 
would be evaluated. 20 Chinese tertiary hospitals accredited to ISO 15189 took part in 
this work. The commercial random access platforms included: Olympus (8 labs), Hitachi 
(6 labs) and Roche (6 labs). To compare the acceptable rates, Chi square test was used.
Results: The statistical analysis results are as follows: (1) Coefficient of variations are 
between 2.8 and 3.9 %, with the slopes and intercepts of regression functions between 
0.928 to 1.064 and −0.174 to 0.630, respectively. (2) The percentage of robust z-scores 
between −2 and 2 is bigger than 90 %. (3) The total percentages of differences on 
all the MDLs are: less than optimal was 31.7 % (19/60); less than desirable was 60.0 % 
(36/60); less than minimum was 65.0 % (39/60); more than minimum was 35.0 % 
(21/60). In this study, 2 laboratories (Nos. 8 and 16) were considered as poor perfor-
mance by z-scores. 10 laboratories (Nos. 4, 5, 7, 8, 9, 10, 11, 14, 16 and 19) have unac-
ceptable measurement errors on MDLs. 10 laboratories (Nos. 1, 2, 3, 6, 12, 13, 15, 17, 18, 
20) can achieve mutual recognition of serum glucose testing results, including: 5 (5/8) 
Olympus, 2 (2/6) Hitachi and 3 (3/6) Roche. There was no significant difference among 
acceptable rates of the three measurements systems for the serum glucose assay.
Conclusions: Traditional statistical analysis, robust statistics and robust z-score, fitting 
linear regression equations and calculating differences on different MDLs can be used 
on studying the comparability and mutual recognition of clinical chemistry analytes 
among hospitals or laboratories in China. The mutual recognition and interchangeabil-
ity of results remains jeopardized even among tertiary hospitals in China. More works 
and efforts should be done for improvement of the current situation of interchange-
ability of results in clinical laboratories in China.
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Background
The results of clinical laboratory tests can reflect the health status of patients, which 
are critical diagnostic evidences for clinicians. Performing accurate and precise meas-
urements that are comparable over time and location and across assays is essential for 
ensuring appropriate clinical and public health practice (Stepman et al. 2014). Mutual 
recognition in clinical laboratory field is an agreement by which two or more labora-
tories agree to recognize one another’s test results of the same patient in a relatively 
short period, it is an aim of the health system. Before implementing mutual recognitions 
of clinical test analytes in China, patients were subjected to the same measurements 
repeatedly in different hospitals in a short period. These redundant measurements 
were not only a waste of time and medical expense, but also stressed patients due to 
repeated blood or other human sample collections. If the test results of different lab-
oratories could achieve mutual recognition, analytes would not need to be duplicated 
measured in a reasonable short period. Mutual recognition is a regional agreement by 
which two or more laboratories agree to recognize one another’s testing results. In this 
article, 20 Chinese tertiary hospitals attended this study, and 14 clinical chemistry ana-
lytes were included. These analytes are (in serum): Alanine aminotransferase, Aspartate 
aminotransferase, Alkaline phosphatase, Glutamyltransferase, Lactate dehydrogenase, 
Creatine kinase, Urea nitrogen, Creatinine, Uric acid, Glucose, Total protein, Albumin, 
Cholesterol and Triglycerides. The analyte of serum glucose was used as the example 
for the statistical methodology study. In this article, the statistical methods and param-
eters, which may be useful for inter-laboratory comparison in China, would be calcu-
lated and analyzed, include: traditional statistical analysis of raw data, robust statistics 
and robust z-score, fitting linear regression equations and differences on medical deci-




The study involved use of leftover patient samples which were all de-identified during 
the collection. It was also ensured that appropriate amount of serum was collected from 
each patient sample so that a certain volume was left for possible repetition of measure-
ment. The use of patient samples in the present study has been reviewed and approved 
by the Ethics Committee of Beijing Hospital and Shanghai Zhongshan Hospital. The 
authors and the related laboratories staffs confirmed that all subjects had given their 
consent to participate in this study even if the samples were the leftover samples from 
outpatient department. Our study adhered to strict ethical guidelines as set out by com-
mittee on publication ethics (COPE, http://publicationethics.org/).
Laboratories and samples
We performed this study with 10 fresh-frozen single donation serum samples obtained 
from Shanghai Zhongshan hospital. Serum was collected according to the CLSI protocol 
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C37-A without filtration and with 2 U/mL human thrombin (Sigma-Aldrich) added to 
the serum to facilitate clotting at room temperature (Wayne 1999). The individual blood 
donations were tested and found negative for anti-HIV I/II, anti– hepatitis C virus, and 
hepatitis B surface antigen. Immediately after 2-mL portions of the sera were aliquoted 
into polypropylene vials, the sera were stored at −70  °C and kept under these storage 
conditions until shipment on dry ice to the participating laboratories. The samples were 
required to be kept frozen until analysis. The participants (20 tertiary hospitals) each 
received 1 aliquot of the 10 samples, which was sufficient for analysis of the 14 analytes 
twice. The manufacturers/test systems used by participants were: Olympus AU (the 
serial numbers of labs were 1, 2, 11, 12, 15, 16, 17 and 19, n =  8), Hitachi (3, 4, 5, 7, 
8 and 18, n = 6), and Roche Cobas (6, 9, 10, 13, 14 and 20, n = 6). The homogeneity 
and stability of the samples were guaranteed by National Center for Clinical Laborato-
ries (NCCL) which prepared the samples as fresh frozen blood and had been approved 
by China National Accreditation Service for Conformity Assessment (CNAS) for ISO 
17043. To compare the acceptable rates among measurement systems, Chi square (χ2) 
test was used. A p < 0.05 was considered significant.
Traditional statistics and data treatment
All numerical results were converted to SI units. After calculating the median, arithme-
tic mean, standard deviation (s), coefficient of variation (CV), minimum and maximum, 
test results exceeding the range of arithmetic mean ± 3 times of s were considered as 
outliers and eliminated.
Robust statistics analysis
Robust statistics (International Standard Organization 2005) are statistics that emulate 
popular statistical methods, but they are not affected by outliers or other small depar-
tures from model assumptions. Robustness is a property of the estimation algorithm, 
not the estimates it produces; therefore it is not strictly correct to call the averages and s 
calculated by such an algorithm robust. In order to avoid the use of excessively cumber-
some terminology, the robust average and robusts should be understood in ISO 13528 
as “mean estimates of the population mean” or “mean estimates of the population stand-
ard deviation calculated using a robust algorithm”. The robust estimates average and s 
were derived from an iterative calculation by updating the values of average and s several 
times from the modified data until the process converged.
The algorithm of robust average and robust s of robust statistics could be concisely 
described as below (International Standard Organization 2005):
Denote the submitted results of one lot, sorted into increasing order, by:
Denote the robust average and robust s of these data by x∗ and s∗.
Calculate initial values for x∗ and s∗ as:
x1, x2, . . . , xi, . . . , xp
x∗ = median of xi (i = 1, 2, 3, 4 . . . , p)
s∗ = 1.483 × median of
∣∣xi − x∗
∣∣ (i = 1, 2, 3, 4 . . . , p)
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Update the values of x∗ and s∗ as follows. Calculate:
For each xi (i = 1, 2, 3, 4…, p), calculate:
Calculate the new value of x∗ and s∗ from:
where the summation is over i.
The robust estimates x∗ and s∗ may be derived by an iterative calculation, i.e. by updat-
ing the value of x∗ and s∗ several times using the modified date, until the process con-
verges. Convergence may be assumed when there is no change from one iteration to 
the next in the third significant figure of the robust s and of the equivalent figure in the 
robust average.
Creating regression equation
The median of the results from each sample lot was treated as the independent variable 
(X), while the arithmetic average of the two test results was treated as the dependent 
variable (Y). Each regression equation for each laboratory was based on the median and 
its test results, Y = k∗X + b; where k is the slope, and b is the intercept.
The differences of each MDL
The differences were calculated according to the regression equation and the MDLs of 
serum glucose, namely 2.50, 6.67 and 10.00 mmol/L (Statland 1987). The MDLs treated 
as independent variable (X) were brought into the regression equation to calculate the 
dependent variable (Y): the differences (%) =  (Y − MDL)/(MDL) × 100 %. Compared 
to the desirable, optimum and minimum allowable differences derived from biological 
variation data (Joana et al. 2014), the inter-laboratory test results comparability and the 
differences on MDLs would be evaluated comprehensively.
Calculating robust Z‑score for every laboratories
Z-score is the standardized measurement of laboratory bias, which is calculated using 
the assigned value and the standard deviation for proficiency assessment. In this arti-
cle, robust z-score (International Standard Organization 2005) was derived from the 
robust averages and robust s, and the formula for the robust z-score in this article is thus 
z = (x − X)/σ = (x – x∗)/s∗, where x is the test results, X is the averages of x, σ is the s, 
x∗ is the robust averages, and s∗ is the robust s. Two or more robust z-scores of these 10 




x∗ − δ, if xi < x
∗
− δ
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lots of one laboratory above 2 or below −2, shall be considered as poor performance and 
cannot be recognized with others.
Results
Traditional statistics
Only two single outliers were determined in lot 10, and the rest of the results were all in 
the range of arithmetic mean ± 3 times of s, for details please see Table 1.
The regression equations and differences of each MDL
After creating regression equations and substituting each MDL into the equations, the 
differences of each MDL for each of the 20 laboratories were calculated. The allowable 
differences of optimal, desirable and minimum of serum glucose were 1.17, 2.34 and 
3.51 %, respectively, which were calculated from CVw (within-subject biologic variation) 
and CVg (between-subject biologic variation) of 2014 (Statland 1987). There were only 
31.7 % (19/60) differences less than the optimal allowable bias, and 60.0 % (36/60) differ-
ences less than the desirable allowable differences and 65.0 % (39/60) for the minimum, 
suggesting there were more than 1/3 (21/60) differences that failed to meet the mini-
mum allowable differences, see Table 2 and Fig. 1 for details. 10 laboratories (Nos. 4, 5, 7, 
8, 9, 10, 11, 14, 16 and 19) have unacceptable measurement errors on MDLs.
Robust statistical results and robust Z‑scores
Robust statistical results and the range of robust z-scores were listed in Table  3. The 
range of robust averages of all lots of samples were from 5.126 to 14.434 (mmol/l), robust 
standard deviations were from 0.179 to 0.433 with the change in the robust averages, 
and z-scores were from −2.895 to 5.356, except that lot 1 was only 80 % (16/20) of robust 
z-score in the range of −2 to 2 and others were no less than 90 % (18/20). The laborato-
ries of Nos. 8 and 16 have two or more robust z-scores out of the range of −2 to 2.
Laboratories/measurement systems performance
In this study, 10 laboratories (Nos. 4, 5, 7, 8, 9, 10, 11, 14, 16 and 19) have unaccepta-
ble measurement errors on MDLs of serum glucose. There were 3 (Nos. 11, 16 and 19) 
for Olympus AU, 4 (Nos. 4, 5, 7 and 8) for Hitachi and 3 (Nos. 9, 10 and 14) for Roche 
Table 1 The traditional statistics of glucose test results (mmol/l)
a The maximum is not including the outliers
Lot n Arithmetic mean Median s CV (%) Maximum Minimum
1 40 6.02 6.00 0.23 3.8 6.43 5.54
2 40 7.13 7.11 0.26 3.6 7.90 6.62
3 40 5.12 5.11 0.19 3.8 5.58 4.67
4 40 5.74 5.75 0.21 3.6 6.09 5.18
5 40 6.67 6.65 0.26 3.9 7.10 6.00
6 40 7.62 7.62 0.28 3.6 8.15 6.90
7 40 8.79 8.80 0.26 2.9 9.37 8.14
8 40 9.94 9.97 0.30 3.0 10.55 9.06
9 40 14.42 14.50 0.40 2.8 15.27 13.43
10 38 11.98 11.96 0.39 3.2 12.75a 11.09
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Cobas. There was no significant difference among acceptable rates of the three measure-
ments systems for the serum glucose assay (data were not shown).
Discussion
All hospitals and laboratories are eager to perform well. In order to achieve perform-
ing accurate and precise measurements, one method is to use assays that are metro-
logically traceable to a higher-order reference measurement system or harmonized by 
use of internationally recognized procedures (Vesper and Thienpont 2009; Miller et al. 
2011). In Europe, the European Union Directive on in vitro diagnostic medical devices 
Table 2 The regression equations and the differences in MDLs
No. of lab Regression equa‑
tion
Slope Intercept Correlation Differences in MDLs 
(%)
Conclusion
Coefficient MDL1 MDL2 MDL3
1 y = 1.014*x − 0.002 1.014 −0.002 0.9999 1.32 1.37 1.38 All less than 
desirable
2 y = 1.008*x − 0.044 1.008 −0.044 0.9997 −0.96 0.14 0.36 All less than 
optimal
3 y = 1.007*x + 0.053 1.007 0.053 0.9997 2.82 1.49 1.23 Two less than 
desirable
4 y = 0.989*x − 0.072 0.989 −0.072 0.9999 −3.98 −2.18 −1.82 Two less than 
desirable
5 y = 1.020*x + 0.158 1.020 0.158 0.9998 8.32 4.37 3.58 All bigger than 
min
6 y = 1.018*x − 0.009 1.018 −0.009 0.9994 1.44 1.67 1.71 All less than 
desirable
7 y = 0.968*x − 0.029 0.968 −0.029 0.9999 −4.36 −3.63 −3.49 One less than 
min
8 y = 0.938*x − 0.120 0.938 −0.120 0.9997 −11.00 −8.00 −7.40 All bigger than 
min
9 y = 1.011*x + 0.100 1.011 0.100 0.9994 5.10 2.60 2.10 Two less than 
min
10 y = 0.963*x − 0.042 0.963 −0.042 0.9999 −5.38 −4.33 −4.12 All bigger than 
min
11 y = 0.928*x + 0.630 0.928 0.630 0.9975 18.00 2.25 −0.90 Two less than 
desirable
12 y = 0.988*x + 0.046 0.988 0.046 0.9999 0.64 −0.51 −0.74 All less than 
optimal
13 y = 1.011*x − 0.007 1.011 −0.007 0.9999 0.82 1.00 1.03 All less than 
optimal
14 y = 1.064*x − 0.042 1.064 −0.042 0.9800 4.72 5.77 5.98 All bigger than 
min
15 y = 0.982*x + 0.030 0.982 0.030 0.9996 −0.60 −1.35 −1.50 All less than 
desirable
16 y = 1.055*x + 0.016 1.055 0.016 0.9998 6.14 5.74 5.66 All bigger than 
min
17 y = 0.993*x − 0.001 0.993 −0.001 0.9996 −0.74 −0.71 −0.71 All less than 
optimal
18 y = 0.964*x + 0.133 0.964 0.133 0.9999 1.72 −1.61 −2.27 All less than 
desirable
19 y = 1.029*x − 0.174 1.029 −0.174 0.9998 −4.06 0.29 1.16 Two less than 
optimal
20 y = 0.989*x + 0.025 0.989 0.025 0.9995 −0.10 −0.73 −0.85 All less than 
optimal
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requires demonstration of metrological traceability (Directive 98/79/EC of the European 
Parliaments and of the Council of 27 October 1998). However, the intrinsic quality of 
a manufacturer’s assay or test system might be confounded by the laboratory using the 
system. German health reports showed that the unnecessarily repeated clinical labora-
tory tests cost 1.5 billion US dollars annually in 1998, while the United States cost 7.4 bil-
lion US dollars converted by the US GDP level. In 2004, NIST “The impact of calibration 
error in medical decision making (Final Report)” showed that only for one clinical test 
Fig. 1 The differences of each medical decision level for all attended laboratories
Table 3 The robust statistics and robust z-scoresa of glucose test results
a The z-score in this table have been derived from the data in column “Robust average” and “Robust s”. The formula for the 
z-score in this table is z = (x − x∗)/s∗
Lot Robust average Robust s Range of robust z‑scores The percentage 
of |z‑score| ≤2
1 6.009 0.179 −2.397 to 2.268 80 % (16/20)
2 7.117 0.209 −2.354 to 3.124 90 % (18/20)
3 5.126 0.186 −2.102 to 1.957 95 % (19/20)
4 5.746 0.193 −2.881 to 1.731 95 % (19/20)
5 6.683 0.264 −2.379 to 1.390 95 % (19/20)
6 7.630 0.254 −2.795 to 2.008 90 % (18/20)
7 8.795 0.209 −2.895 to 2.656 90 % (18/20)
8 9.949 0.270 −2.793 to 2.133 90 % (18/20)
9 14.434 0.377 −2.517 to 2.125 90 % (18/20)
10 12.026 0.433 −2.023 to 5.356 90 % (18/20)
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analyte—serum total calcium, the additional cost of calibration error was 0.06–0.199 bil-
lion US dollars (Michael). Duplicated clinical laboratory tests within a short period will 
result in the rising dissatisfaction of the patients to the healthcare providers and dis-
crepancies in test results between different hospitals or from different instruments may 
directly lead to incorrect diagnosis or medical disputes.
The CV is a normalized measure of dispersion of a quantitative data. In this study the 
CVs were quite small which means the dispersion and differences among test results of 
all the laboratories were small. But currently there is no evaluation standard for evaluat-
ing the CVs of test results of more than one laboratory. The smaller CVs are, the better 
consistency of the test results are. The slopes (the closer to 1 the better) were used to 
evaluate the ratio errors of measurement system and intercepts (the closer to 0 the bet-
ter) for evaluating the systematic errors. The performance of laboratory cannot be evalu-
ated only by slope and intercept; the difference on the MDL which can be calculated 
by the regression equation is a useful indicator of performance statistics for laboratory. 
In this study, 10 laboratories (Nos. 4, 5, 7, 8, 9, 10, 11, 14, 16 and 19) have unacceptable 
measurement errors on MDLs. There were 3 labs for Olympus AU, 4 for Hitachi and 3 
for Roche Cobas. There was no significant difference among acceptable rates of the three 
measurements systems for the serum glucose assay. Not same as the previous study in 
development country (Stepman et al. 2014). 10 laboratories (Nos. 1, 2, 3, 6, 12, 13, 15, 17, 
18, 20) can achieve mutual recognition of serum glucose testing results and their differ-
ences on MDLs can be accepted.
In this study, arithmetic mean, median and robust average had little difference com-
pared with each other in every lot of sample, which means that the dispersion of the 
results was small, and the distribution of the results was relatively concentrated.
When a participant reports a result that gives rise to z-score above 2 or below −2, then 
the result shall be considered to give a “warning signal”. In this study, two or more “warn-
ing signals” in one laboratory, shall be taken as evidence that an anomaly has occurred 
that requires investigation. In this study, 2 laboratories (Nos. 8 and 16) were considered 
as poor performance by z-scores.
To achieve the mutual recognition of clinical test results, the clinical laboratories 
should perform their daily work and management according to ISO 15189 as much as 
possible, internal quality control and external quality assessment should be performed 
timely, and the reference intervals should be the same with each other (Wang et  al. 
2011). On such basis, fresh clinical samples could be used to study the comparability 
of the results between the laboratories under the mutual recognition. In this article, we 
introduced the statistical methods and analyses including traditional statistics, robust 
statistics and robust z-scores, to create regression equations and calculate the differ-
ences of each laboratory in MDLs. The traditional and robust statistics described the 
basic information of the raw data, with the latter hardly affected by the outliers; robust 
z-scores described the locations of each test result in the overall data; the regression 
equations calculated the systemic errors of every laboratory in MDLs (the medical deci-
sion levels were substituted into the regression equation to evaluate the differences in 
MDLs). The methods described here were relatively intuitive and simple, easily applica-
ble to office software or statistical software.
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In this article we took the analyte of glucose as an example. The s and CVs (the test 
results differences between laboratories and the dispersion of the overall test results) 
were small in traditional and robust statistics. In total, more than 90  % of the robust 
z-scores were in the range of −2 to 2. They not only showed that the locations of every 
laboratory test results were within the overall results, but also indicated their differences 
from the robust averages. The three MDLs for glucose were 2.50, 6.67 and 10.00 mmol/l, 
and the allowable differences derived from biological variation data of optimal, desirable 
and minimum were 1.17, 2.34 and 3.51 %, respectively. In the MDLs for every attended 
clinical laboratory, there were only 31.7  % (19/60) of differences that met the optimal 
allowable difference, while 60.0  % (36/60) and 65.0  % (39/60) of differences that just 
couldmeet the desirable and minimum allowable differences, respectively. If one or more 
difference of a laboratory is more than minimum allowable difference, that shall be taken 
as poor performance that requires improvement. The smaller difference a laboratory 
had, the better comparability it would have and less difference could be found between 
this laboratory and overall ones. All the twenty laboratories demonstrated good linear 
and correlation with the entire concentration range: the slopes were close to 1 and the 
intercepts were close to 0, meanwhile the correlation coefficients tended to be 1. The sta-
tistical evaluation of robust z-scores was different from the differences evaluation of the 
regression equations because the statistical performance of robust statistics was not the 
same as traditional statistics.
In conclusion, all the statistical analysis methods mentioned in this article were 
designed for comparison and mutual recognition of clinical chemistry analytes. Calcu-
lating z-scores, fitting linear regression equations and calculating differences on different 
MDLs were used, and 10 laboratories were considered to achieve mutual recognition 
of the test results of serum glucose. All the statistical methods obtained good perfor-
mances in the study of clinical chemistry analytes for comparison and mutual recog-
nition among hospitals or laboratories using frozen fresh clinical samples. The mutual 
recognition and interchangeability of results remains jeopardized even among tertiary 
hospitals in China. More works and efforts should be done for improvement of the cur-
rent situation of interchangeablity of results in clinical laboratories in China.
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